TME Pharma N.V. (EPA:ALTME)

Market Cap	7.25M +6.9%
Revenue (ttm)	27.00K
Net Income	-4.58M
EPS	-0.07
Shares Out	94.09M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	221,615
Average Volume	339,278
Open	0.0780
Previous Close	0.0794
Day's Range	0.0770 - 0.0798
52-Week Range	0.0490 - 0.1480
Beta	0.77
RSI	54.56
Earnings Date	Apr 23, 2026

About TME Pharma

TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. The company’s Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, and glioblastoma. It also developing NOX-E36, which has completed Phase 1/2a clinical trial for the treatme...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1997
• Employees: 12
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALTME